Fundz

Who to call at Liminatus Pharma, Inc., and when

Fundz watches for the moments Liminatus Pharma, Inc. starts buying, and tells you who to reach.

  • An alert the day Liminatus Pharma, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Liminatus Pharma, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Liminatus Pharma, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Liminatus Pharma, Inc.

The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.

liminatuspharma.com
Filed: Nov 3, 2026La Palma, CaliforniaCIK: 0001971387Biotechnology
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Liminatus Pharma secured $650,002.50 in private placement funding by issuing 260,001 shares at $2.50 per share to a non-U.S. investor, with closing expected November 20, 2026. The capital will support working capital and general corporate operations.

Quick answer

Liminatus Pharma, Inc. filed a Form 8-K with the SEC on November 3, 2026 under Item 1.01 (Entry into Material Agreement). Liminatus Pharma secured $650,002.50 in private placement funding by issuing 260,001 shares at $2.50 per share to a non-U.S. investor, with closing expected November 20, 2026.

What did Liminatus Pharma, Inc. disclose in its 8-K filed November 3, 2026?
Liminatus Pharma secured $650,002.50 in private placement funding by issuing 260,001 shares at $2.50 per share to a non-U.S. investor, with closing expected November 20, 2026. The capital will support working capital and general corporate operations.
What does 8-K Item 1.01 (Entry into Material Agreement) mean?
The company signed a major contract or deal. Companies generally must file it within four business days of the event.
Which other companies filed an 8-K Item 1.01 around the same time?
OpenWorld, Inc. (October 30, 2026) also filed an Item 1.01 8-K within a week of Liminatus Pharma, Inc.
Where can I read the original Liminatus Pharma, Inc. filing?
The original filing is on SEC EDGAR (CIK 0001971387), accession number 0001104659-26-122012.

Source: Fundz verified event record.

Other companies that filed an 8-K Item 1.01 (Entry into Material Agreement) the same week

Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.

  • OpenWorld, Inc. (October 30, 2026): OpenWorld appointed Patrick Kim as CEO of Blocksight effective October 27, 2026, following the company's merger.

Key Takeaways

Company raised $650,002.50 through private placement of 260,001 common shares at $2.50 per share

Investor is a non-U.S. entity, indicating international investor interest in the company

2 more takeaways

Filing Overview

Form Type8-K
Filing DateNov 3, 2026
Item1.01
CategoryMaterial Agreement
CIK0001971387
Accession #0001104659-26-122012
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offeringmaterial agreement

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings

Liminatus Pharma, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.